Gastrin releasing peptide receptor targeted nano-graphene oxide for near-infrared fluorescence imaging of oral squamous cell carcinoma

Li, Ran; Gao, Ruifang; Wang, Yimei; Liu, Zhuanzhuan; Xu, Hang; Duan, Ailin; Zhang, Fang; Ma, Lixin

doi:10.1038/s41598-020-68203-y

Cited by 23 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DOX@NGO-BBN-AF750 exhibited good water dispersity. The size and overall nanoparticle morphology of DOX@NGO-BBN-AF750 were similar to those of NGO and NGO-BBN-AF750 observed under TEM ( 48 ). The nanoparticles appeared as two-dimensional flacks with the diameter range of 0.5–5 µm and thickness of 0.8–1.2 nm.…”

Section: Resultssupporting

confidence: 59%

“…First, NGO-BBN-AF750 nanoprobes were synthesized and purified according to the procedures in our previous article ( 48 ). Briefly, NGO-COOH and AF750-6Ahx-Sta-BBN were added in Tris–HCl buffer, stirred for 40 min in the dark, and centrifuged, and the supernatant was removed to obtain NGO-BBN-AF750.…”

Section: Methodsmentioning

confidence: 99%

“…In recent years, receptor antagonists have been developed and studied by modifications on the C terminal amino acids of BBN for the diagnosis and treatment of tumors ( 46 , 47 ). We have previously shown that BBN antagonist peptides conjugated to Alexa Fluor 750 (BBN-AF750) have high binding affinity and specificity to GRPR-overexpressed tumors ( 46 ), including human OSCC biopsies and HSC-3 cells ( 48 ). We further demonstrated that nano-graphene oxide (NGO) coupled with BBN-AF750 peptides (NGO-BBN-AF750) specifically targets GRPR in human HSC-3 cells ( 48 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Gao

Zhao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is the most common type of cancer occurring in the oral and maxillofacial regions. Despite of the advances in the diagnosis and treatment, the overall 5-year survival rate has remained about 40%–50% in the past decades. Various nanotechnology-based carrier systems have been investigated for their potentials in the OSCC treatment. However, because of the lack of active targeting of tumors, their application is limited. Studies have shown that gastrin-releasing peptide receptors (GRPRs) are overexpressed on many human cancers, including head and neck squamous cell carcinoma. Herein, we aimed to develop a GRPR-targeted nano-graphene oxide (NGO) nanoprobe drug delivery system for OSCC therapy. DOX@NGO-BBN-AF750 was synthesized by the non-covalent bonding method to couple carboxylated NGO with BBN-AF750 (bombesin antagonist peptides conjugated to Alexa Fluor 750) and DOX (doxorubicin) through π-π and hydrogen bonding. Internalization and antitumor activities were carried out in human HSC-3 cancer cells. The tumor pH microenvironment was simulated to study the release of antitumor drug DOX from the DOX@NGO-ant BBN-AF750 complex under different pH conditions. DOX@NGO-BBN-AF750 showed internalization into HSC-3 cells. The IC50 (50% inhibitory concentration) was 5 µg/ml for DOX@NGO-BBN-AF750 in HSC-3 cells. Furthermore, DOX@NGO-BBN-AF750 showed a pH-sensitive drug release rate, and a dose-dependent and pH-responsive cytotoxicity in HSC-3 cells. DOX@NGO-BBN-AF750 presents the characteristics ensuring a slow release of DOX from the nanoprobe, thereby protecting the drug from degradation and prolonging the half-life of the drug. This report provides a versatile strategy to achieving targeted and imaging-guided therapy of OSCC.

show abstract

Section: Resultssupporting

confidence: 59%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Gao

Zhao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, NGO-BBN-AF750 showed good cellular internalization capabilities compared to the peptide antagonist AF750-6Ahx-Sta-BBN. This work revealed how nanoparticle-based delivery systems can enable OSCC-targeted near-infrared fluorescence imaging in a non-invasive manner [ 164 ].…”

Section: Nanocarriers For Hnc Diagnosis and Treatmentmentioning

confidence: 99%

Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment

2022

View full text Add to dashboard Cite

Head and neck cancers rank sixth among the most common cancers today, and the survival rate has remained virtually unchanged over the past 25 years, due to late diagnosis and ineffective treatments. They have two main risk factors, tobacco and alcohol, and human papillomavirus infection is a secondary risk factor. These cancers affect areas of the body that are fundamental for the five senses. Therefore, it is necessary to treat them effectively and non-invasively as early as possible, in order to do not compromise vital functions, which is not always possible with conventional treatments (chemotherapy or radiotherapy). In this sense, nanomedicine plays a key role in the treatment and diagnosis of head and neck cancers. Nanomedicine involves using nanocarriers to deliver drugs to sites of action and reducing the necessary doses and possible side effects. The main purpose of this review is to give an overview of the applications of nanocarrier systems to the diagnosis and treatment of head and neck cancer. Herein, several types of delivery strategies, radiation enhancement, inside-out hyperthermia, and theragnostic approaches are addressed.

show abstract

“…This new nanocarrier showed in vitro cellular uptake and killing potential for some cancer cell lines ( Liu et al, 2008 ). Subsequently, GO was conjugated with biopolymers ( Mirzaie et al, 2019 ), biomolecules ( Li R. et al, 2020 ), metals ( Kordi et al, 2019 ; Cobos et al, 2020 ), and metal oxides ( Luo Y. et al, 2019 ; Pramanik et al, 2019 ) to create intelligent nanoplatforms able to respond at every stage of the cancer treatment process, from targeting to imaging and therapy. Recently Burnett et al (2020) considered, for the first time, GO not as a platform for drug transport or photothermal therapy, but as the therapy itself on human osteosarcoma cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Methods to Scale Down Graphene Oxide Size and Size Implication in Anti-cancer Applications

Tufano

Vecchione

Netti

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Despite considerable progress in the comprehension of the mechanisms involved in the origin and development of cancer, with improved diagnosis and treatment, this disease remains a major public health challenge with a considerable impact on the social and economic system, as well as on the individual. One way to improve effectiveness and reduce side effects is to consider responsive stimuli delivery systems that provide tailor-made release profiles with excellent spatial and temporal control. 2D nanomaterials possess special physicochemical properties (e.g., light, ultrasonic and magnetic responses) and biological behaviors such as endocytosis, biodistribution, biodegradation, and excretory pathways, which lead to their use in various biomedical applications. In particular, among 2D nanomaterials, graphene and its derivatives, namely graphene oxide (GO) nanomaterials, have attracted enormous attention in cancer diagnosis and therapy because they combine, in a unique material, extremely small size, NIR absorption, delocalized electrons, extremely high surface area, and versatile surface functionality. Taking into account the fundamental role played by GO size, in this review, we summarize the main methods employed to reduce and homogenize in nanometric scale the lateral dimensions of graphene oxide produced by chemical exfoliation of graphite, as well as post-synthesis separation techniques to uniform the size. We also discuss the implication of the small size in cancer treatment by exploiting GO nanocarriers as an effective theranostic tool.

show abstract

Gastrin releasing peptide receptor targeted nano-graphene oxide for near-infrared fluorescence imaging of oral squamous cell carcinoma

Cited by 23 publications

References 39 publications

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment

Methods to Scale Down Graphene Oxide Size and Size Implication in Anti-cancer Applications

Contact Info

Product

Resources

About